Geographic and Sociodemographic Variations in Prevalence of Mental Health Symptoms Among US Youths, 2022

Accepted: May 23, 2023
Published Online: September 06, 2023

Objectives. To assess geographic and sociodemographic variations in prevalence of mental health symptoms among US youths.

Methods. We analyzed data from the Household Pulse Survey, phases 3.5 and 3.6, between June 1 and November 14, 2022. The sample included 103 296 households with an estimated 190 017 youths younger than 18 years. We defined mental health symptoms based on parental responses and estimated prevalence by state and subgroups, including race/ethnicity, parental education, household income, housing tenure, household food sufficiency, and health insurance coverage. All analyses incorporated sampling weight.

Results. An estimated 34.5% (95% confidence interval [CI] = 33.7%, 35.3%) of youths had parent-reported mental health symptoms. The prevalence of symptoms varied across states, ranging from 27.9% (95% CI = 23.8%, 32.0%) in Florida to 46.4% (95% CI = 41.9%, 50.9%) in New Hampshire. We observed variations by subgroup, with youths in households that did not pay rent reporting a prevalence of 43.8% (95% CI = 39.3%, 48.4%) and those experiencing food insufficiency reporting a prevalence of 56.0% (95% CI = 50.9%, 61.2%).

Conclusions. There is an urgent need for attention to mental health challenges among youths, taking into account geographic and sociodemographic variations. (Am J Public Health. 2023;113(10):1116–1119. https://doi.org/10.2105/AJPH.2023.307355)

TOOLS

Downloaded 374 times

SHARE

ARTICLE CITATION

Junxiu Liu, Zhiyang Zhou, Xi Cheng, Nita Vangeepuram, "Geographic and Sociodemographic Variations in Prevalence of Mental Health Symptoms Among US Youths, 2022", American Journal of Public Health 113, no. 10 (October 1, 2023): pp. 1116-1119.

https://doi.org/10.2105/AJPH.2023.307355

PMID: 37672739

  1. Potential of angiotensin II receptor blocker telmisartan in reducing mortality among hospitalized patients with COVID-19 compared with recommended drugs
    Dengyuan Liu et al., Cell Discovery, 2022
  2. Disease profile and plasma neutralizing activity of post-vaccination Omicron BA.1 infection in Tianjin, China: a retrospective study
    Hong Zheng et al., Cell Research, 2022
  3. Extended follow-up of a phase 2 trial of xevinapant plus chemoradiotherapy in high-risk locally advanced squamous cell carcinoma of the head and neck: a randomised clinical trial
    Yungan TAO et al., European Journal of Cancer, 2023
  4. Extended follow-up of a phase 2 trial of Xevinapant plus chemoradiotherapy in high-risk locally advanced squamous cell carcinoma of the head and neck: a randomised clinical trial
    Yungan TAO et al., EJC, 2023

American Journal of Public Health®
800 I Street NW, Washington, DC 20001-3710
202-777-2742

Print ISSN: 0090-0036 | Electronic ISSN: 1541-0048
© 2023 American Public Health Association

During your search of AJPH content, a Scorecard Research survey may pop-up. This survey is optional, and you may opt out of receiving future survey requests by clicking the "opt-out" link.

Powered by Atypon® Literatum